OTCM
CYAN
Market cap3mUSD
Oct 07, Last price
0.53USD
1D
0.00%
1Q
2.93%
Jan 2017
-87.67%
Name
Cyanotech Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids. Beyond its product lines, Cyanotech also offers contract extraction services. The company reaches its customers through a diverse array of sales channels, encompassing third-party distributors, retailers, and online platforms, as well as direct sales to consumers. Additionally, it supplies products in bulk to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries.
Key people
Michael Davis
Independent Chairman of the Board · since 2011
Gerald Cysewski
Chief Executive Officer Emeritus, Chief Scientific Officer · since 2022
Jennifer Rogerson
Chief Financial Officer, Vice President - Finance and Administration, Treasurer · since 2025
Glenn Jensen
Vice President - Operations · since 2019
Charles Hartmann
Vice President of Sales and Marketing · since 2021
Jennifer Johansen
Vice President - Quality, Regulatory and Government Affairs · since 2010
Amy Nordin
Vice President of Human Resources, Corporate Secretary · since 2019
Jennifer Brand
Vice President - Sales · since 2025
Collette Kakuk
Chief Strategic and Commercial Officer · since 2023
Matthew Custer
President, Chief Executive Officer, Director · since 2022
Angela Mcelwee
Independent Director · since 2021
David Mulder
Independent Director · since 2016
David Vied
Independent Director · since 2015
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||